blog

By: Ryan Crisman, Ph.D., co-founder and Chief Technical Officer IntroductionIn the fast-paced landscape of biotechnology, the demand for advanced tools and techniques is on a relentless rise. Lentiviral vectors (LVVs), which are a cornerstone in immunology and cell and gene therapy, have garnered significant attention due to their versatility and potential applications in cancer, genetic …

Building internal manufacturing as a preclinical company Read More »

By: Teisha Rowland, Ph.D., Principal Scientist Last fall, I felt a lump in my breast. After debating for a few days about what to do – Had it been there before, and I just hadn’t noticed it? Should I be concerned about it? – I ended up calling my Obstetrics and Gynecology (OBGYN) physician’s office. …

Reflecting on Women’s History Month – A look at progress in breast cancer treatments Read More »

Ten years ago, a little girl was in the battle of her life against a foe she couldn’t possibly comprehend. Two years previously, she was diagnosed with acute lymphoblastic leukemia at the age of 5. No parent wants to receive the news that their child has a potentially lethal disease, but for the majority of …

Learning from history – Umoja’s approach to overcoming CAR T therapy treatment challenges and limitations Read More »

A Brief History of the CAR T Cell Field While chimeric antigen receptor (CAR) T cell therapies have revolutionized the treatment of blood-forming tissue cancers (i.e., hematologic malignancies), major limitations hinder their widespread application. Decades of CAR T cell therapy efforts, starting with “first generation” CAR T cell therapies in the 1990s and leading to …

Spotlight on Umoja Biopharma’s Engineered induced Pluripotent Stem Cells (iPSCs) Platform  Read More »

At Umoja, we know that a cancer immunotherapy is only as good as the patients it reaches. We can do the best, most innovative, most exciting science at the bench, but if the manufacturing process is not scalable, the effort will be too large to ultimately meet the needs of all patients who might benefit. …

Out of the Lab, Into the Factory: Providing Cancer Immunotherapy to the Masses Read More »